An mRNA pancreatic cancer vaccine shows promising long-term survival rates in early clinical trials at Memorial Sloan Kettering Cancer Center.
← News
Medicine Breakthroughs Medicine Breakthroughs Health
Investigational Pancreatic Cancer Vaccine Shows Lasting Results in Early Trial, Supporting Continued Testing | Memorial Sloan Kettering Cancer Center
90% % Survival rate at 6 years
Phase 1 Trial phase
Pancreatic Cancer Cancer type